Literature DB >> 6948131

Noncontraceptive estrogen use and the occurrence of ovarian cancer.

N S Weiss, J L Lyon, S Krishnamurthy, S E Dietert, J M Liff, J R Daling.   

Abstract

Female residents of six counties in Washington and Utah in whom ovarian cancer was diagnosed during 1975-79 were interviewed concerning prior use of noncontraceptive estrogens. Interviews with a random sample of women drawn from these counties were obtained for comparison. Taken as a whole, women with epithelial ovarian tumors reported estrogen use for 1 year or more somewhat more often than did controls [relative risk (RR) = 1.3, 95% confidence interval (CL) = 0.9-1.8]. The proportion of women who had used estrogens varied according to the histology of their tumor; notably, of 17 women with endometrioid tumors, 12 had used estrogens (RR = 3.1, 95% CL = 1.0-9.8). The excess risk of endometrioid carcinoma related to estrogen use was not further increased when these hormones were taken for long durations, in high doses, or proximate to the time of diagnosis. Neither was there any evidence of increased risk from estrogen use in the small group of women with clear cell tumors, a histologic tumor type believed to be closely related to endometrioid carcinoma. Thus the observed association between menopausal estrogen use and the occurrence of ovarian endometrioid tumors should be interpreted cautiously until the results of additional studies are available.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6948131

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  19 in total

Review 1.  A risk-benefit assessment of estrogen therapy in postmenopausal women.

Authors:  M P Cust; K F Gangar; T C Hillard; M I Whitehead
Journal:  Drug Saf       Date:  1990 Sep-Oct       Impact factor: 5.606

Review 2.  Hormone replacement therapy in the aged. A state of the art review.

Authors:  S Jacobs; T C Hillard
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

3.  The 2012 hormone therapy position statement of: The North American Menopause Society.

Authors: 
Journal:  Menopause       Date:  2012-03       Impact factor: 2.953

4.  Hormonal aspects of ovarian malignancy.

Authors:  J Waxman
Journal:  J R Soc Med       Date:  1984-03       Impact factor: 5.344

Review 5.  The adverse effects of hormone replacement therapy.

Authors:  A Tavani; C La Vecchia
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

6.  Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review.

Authors:  Y Pan; M S Kao
Journal:  Curr Oncol       Date:  2010-11       Impact factor: 3.677

7.  Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study.

Authors:  G Albrektsen; I Heuch; G Kvåle
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

8.  Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States).

Authors:  A I Adler; N S Weiss; M L Kamb; J L Lyon
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

Review 9.  Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology.

Authors:  Tuya Pal; Jenny Permuth-Wey; Ambuj Kumar; Thomas A Sellers
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 10.  Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.

Authors:  Celeste Leigh Pearce; Karine Chung; Malcolm C Pike; Anna H Wu
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.